Background Although there have been several reports in which central nervous system
(CNS) metastases of non-small cell lung cancer (NSCLC) were improved by erlotinib …

Background: Brain metastases commonly occur in non–small cell lung cancer (NSCLC), and
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor …

Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …

Purpose Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of …

The incidence of brain metastasis (BM) is high in patients with non-small-cell lung cancer.
Available standard therapeutic options, such as whole-brain radiation therapy and systemic …

In our previous work, PC-9-Br, a PC-9 brain seeking line established via a preclinical animal
model of lung cancer brain metastasis (LCBM), exhibited not only resistance to epidermal …

Introduction: Brain metastases (BM) are a common and lethal complication of non-small cell
lung cancer (NSCLC) with up to 40% experiencing this complication. The use of erlotinib, a …

Brain metastases are a common and devastating consequence of disease progression in
patients with non–small cell lung cancer (NSCLC). The epidermal growth factor receptor …

Purpose Patients of non–small cell lung cancer (NSCLC) with brain metastases have limited
treatment options. High-dose erlotinib (HDE) and gefitinib (HDG) have been tried in the past …

Objective Brain metastasis is frequently found in patient with advanced non-small cell lung
cancer. Gefitinib is a inhibitor of epidermal growth factor receptor and can be used for the …